Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Intersect ENT, Inc. (XENT)
|
Add to portfolio |
|
|
|
| Price: |
$27.31
| | Metrics |
| OS: |
33.8
|
M
| |
|
|
| Market cap: |
$923
|
M
| |
-137
|
% ROIC
|
|
Net debt:
|
$92
|
M
| |
|
|
|
EV:
|
$1.02
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($74.2)
|
M
| |
|
|
|
EBIT
|
($78.2)
|
M
| |
|
|
| EPS |
($5.09)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 106.7 | 80.6 | 109.1 | 108.5 | 96.3 | 78.7 | 61.6 | 38.6 |
| Revenue growth | 32.5% | -26.2% | 0.6% | 12.6% | 22.4% | 27.8% | 59.6% | 115.2% |
| Cost of goods sold | 30.0 | 30.3 | 21.8 | 22.6 | 15.5 | 13.0 | 12.3 | 10.2 |
| Gross profit | 76.7 | 50.2 | 87.4 | 85.9 | 80.8 | 65.7 | 49.3 | 28.4 |
| Gross margin | 71.9% | 62.4% | 80.1% | 79.2% | 83.9% | 83.5% | 80.0% | 73.5% |
| Selling, general and administrative | 122.1 | 98.6 | 108.5 | 91.6 | 80.0 | 72.9 | 59.6 | 36.1 |
| Research and development | 27.9 | 19.4 | 24.3 | 19.3 | 18.4 | 18.9 | 16.6 | 10.3 |
| EBIT | -73.3 | -67.7 | -45.4 | -25.0 | -17.6 | -26.1 | -26.9 | -18.1 |
| EBIT margin | -68.6% | -84.0% | -41.6% | -23.1% | -18.3% | -33.2% | -43.7% | -46.8% |
| Pre-tax income | -163.0 | -73.2 | -43.0 | -22.9 | -16.4 | -25.2 | -26.6 | -18.4 |
| Income taxes | -1.7 | -0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 1.0% | 0.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -161.3 | -72.7 | -43.0 | -22.9 | -16.4 | -25.2 | -26.6 | -18.4 |
| Net margin | -151.1% | -90.3% | -39.4% | -21.1% | -17.0% | -32.0% | -43.2% | -47.6% |
| |
| Diluted EPS | ($4.85) | ($2.23) | ($1.37) | ($0.76) | ($0.56) | ($0.89) | ($1.02) | ($1.61) |
| Shares outstanding (diluted) | 33.3 | 32.6 | 31.4 | 30.3 | 29.1 | 28.4 | 26.2 | 11.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|